HealthCap is a reputable European venture capital firm that specializes in investing globally in life sciences. With a track record of success since 1996, HealthCap has raised eight funds and built a strong portfolio of over 125 companies. Their investment strategy focuses on diseases with a high unmet medical need and breakthrough therapies that can make a transformative impact on clinical practice and the lives of patients.

In fact, HealthCap has taken over 45 companies public and completed numerous trade sales. What sets HealthCap apart is their commitment to productivity. Over the last decade, they have consistently conducted over 40 clinical trials and more than 50 pre-clinical studies.

This dedication has resulted in an impressive portfolio of more than 30 market-approved pharmaceutical products and 50 innovative medical devices. These products have brought significant value to patients, physicians, and society as a whole. HealthCap's investment aim is to achieve significant capital appreciation by targeting diseases with high unmet medical needs and focusing on breakthrough therapies.

They have a keen interest in precision medicine, which involves developing tailored treatments for specific patient subgroups. With their extensive scientific and industrial expertise, HealthCap actively supports the growth of their portfolio companies, ensuring management receives the necessary resources to run the business effectively and responsibly. Based in Stockholm and Lausanne, HealthCap boasts a team of dedicated professionals with diverse backgrounds in medicine, finance, and biochemistry.

Their collective knowledge fuels their innovative approach to transforming the treatment landscape and improving the quality of life for patients